Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Amlitelimab study met its goals but results were not meaningfully better than Dupixent ...

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.